



ASX ANNOUNCEMENT
15 November 2011

BNC210 anti-anxiety clinical data presented at *Neuroscience 2011*

Tuesday, 15th November 2011: Bionomics Limited (ASX:BNO) is pleased to announce that the successful Phase Ib panic attack trial results reported on March 30 this year will be presented at the annual Society For Neuroscience conference, *Neuroscience 2011* in Washington DC today.

CEO and Managing Director of Bionomics, Dr Deborah Rathjen commented "This meeting is seen by industry as the premium opportunity to highlight advances in CNS drug development and to learn about the competitive landscape. We are excited by the potential of BNC210 and have ongoing dialogue with potential licensing partners for its continued development."

"For Bionomics, presenting at this highly attended scientific meeting guarantees that our clinical data will get maximum exposure in the international neuroscience community and raise the global profile of BNC210 as an innovative next generation treatment for anxiety and depression."

The presentation will be given by Dr Sue O'Connor, Senior Director CNS Research and BNC210 Project Leader. Highlights of the poster presentation include:

- BNC210 significantly reduced the number & intensity of panic symptoms
- Subjects treated with BNC210 experienced improved recovery, returning to normal emotional status within 10 minutes of the panic attack, compared with 60 minutes on placebo
- Subjects treated with BNC210 were 94% more likely to experience less than 4 panic symptoms compared to placebo treatment

Neuroscience 2011 runs from 12-16 November and focuses on the debut of cutting edge research for the brain and nervous system from around the world. Over 33,000 people are expected to attend.

Poster Title: The novel compound BNC210 reduces Panic Symptom Scale scores in a model of CCK-4 induced panic in healthy volunteers.

Poster Session 684: Mood Disorders: Experimental Therapeutics: Stress, Anxiety, and Resilience; Tuesday 15 November 1:00-5:00 PM

Poster Number: GG27

BNC210 was the subject of two poster presentations at another major international conference recently, the *European College of Neuropsychopharmacology* conference in September.

The posters can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210 which has recently completed Phase Ib clinical trials. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au